University of South Florida

Digital Commons @ University of South Florida
Internal Medicine Faculty Publications

Internal Medicine

2019

Alda-1 Attenuates Hyperoxia-induced Mitochondrial Dysfunction
in Lung Vascular Endothelial Cells
Sahebgowda Sidramagowda Patil
University of South Florida

Helena Hernández-Cuervo
University of South Florida

Jutaro Fukumoto
University of South Florida, jfukumot@usf.edu

Venkata Ramireddy Narala
Yogi Vemana University

Smita Saji
University of South Florida

See next page for additional authors

Follow this and additional works at: https://digitalcommons.usf.edu/intmed_facpub

Scholar Commons Citation
Patil, Sahebgowda Sidramagowda; Hernández-Cuervo, Helena; Fukumoto, Jutaro; Narala, Venkata
Ramireddy; Saji, Smita; Borra, Monica; Alleyn, Matthew; Lin, Muling; Soundararajan, Ramani; Lockey,
Richard; Kolliputi, Narasaiah; and Galam, Lakshmi, "Alda-1 Attenuates Hyperoxia-induced Mitochondrial
Dysfunction in Lung Vascular Endothelial Cells" (2019). Internal Medicine Faculty Publications. 186.
https://digitalcommons.usf.edu/intmed_facpub/186

This Article is brought to you for free and open access by the Internal Medicine at Digital Commons @ University of
South Florida. It has been accepted for inclusion in Internal Medicine Faculty Publications by an authorized
administrator of Digital Commons @ University of South Florida. For more information, please contact
scholarcommons@usf.edu.

Authors
Sahebgowda Sidramagowda Patil, Helena Hernández-Cuervo, Jutaro Fukumoto, Venkata Ramireddy
Narala, Smita Saji, Monica Borra, Matthew Alleyn, Muling Lin, Ramani Soundararajan, Richard Lockey,
Narasaiah Kolliputi, and Lakshmi Galam

This article is available at Digital Commons @ University of South Florida: https://digitalcommons.usf.edu/
intmed_facpub/186

www.aging-us.com

AGING 2019, Vol. 11, No. 12
Research Paper

Alda-1 attenuates hyperoxia-induced mitochondrial dysfunction in
lung vascular endothelial cells
Sahebgowda Sidramagowda Patil1, Helena Hernández-Cuervo1,2, Jutaro Fukumoto1, Venkata
Ramireddy Narala3, Smita Saji1, Monica Borra1, Matthew Alleyn1, Muling Lin1, Ramani
Soundararajan1, Richard Lockey1, Narasaiah Kolliputi1,2, Lakshmi Galam1
University of South Florida, Division of Allergy and Immunology, Department of Internal Medicine, College of
Medicine, Tampa, Florida 33612, United States
2
University of South Florida, Division of Allergy and Immunology, Department of Molecular Medicine, College of
Medicine, Tampa, Florida 33612, United States
3
Department of Zoology, Yogi Vemana University, Kadapa, India
1

Correspondence to: Lakshmi Galam, Narasaiah Kolliputi; email: lgalam@health.usf.edu, nkollipu@health.usf.edu
Keywords: acute lung injury, hyperoxia, ALDH2, Alda-1, HMVEC
Received: March 6, 2019 Accepted: May 31, 2019 Published: June 17, 2019
Copyright: Patil et al. This is an open‐access article distributed under the terms of the Creative Commons Attribution License
(CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and
source are credited.

ABSTRACT
Acute lung injury (ALI) is a major cause of morbidity and mortality worldwide, especially in aged populations.
Mitochondrial damage is one of the key features of ALI. Hyperoxia-induced lung injury model in mice has been
widely used for ALI study because it features many ALI phenotypes including, but not limited to, mitochondrial
and vascular endothelial cell damage. Recently, accumulating evidence has shown that mitochondrial aldehyde
dehydrogenase 2 (ALDH2) has a protective effect against oxidative stress mediated cell damage in epithelial
cells. However, it is not known whether ALDH2 protects against oxidative stress in vascular endothelial cells. In
this current study, we attempted to find the capacity of Alda-1 [(N-(1,3benzodioxol-5-ylmethyl)-2,6- dichlorobenzamide), an ALDH2 activator] to protect against oxidative stress in human microvascular endothelial cells
(HMVEC). HMVEC pretreated with Alda-1 prior to hyperoxic exposure vs non-treated controls showed i) lower
4-hydroxynonenal (4-HNE) levels, ii) significantly decreased expressions of Bax and Cytochrome C, iii) partially
restored activity and expression of ALDH2 and iv) significantly improved mitochondrial membrane potential.
These results suggest that ALDH2 protein in lung vascular endothelial cells is a promising therapeutic target for
the treatment of ALI and that Alda-1 is a potential treatment option.

INTRODUCTION
Aging is a major risk factor that contributes to the
initiation and development of numerous acute and
chronic lung diseases [1]. Aging is related with
physiological decline in lung function and, accordingly,
mortality due to lung disease with age. Acute lung
injury (ALI) is a severe respiratory condition that
affects over 200,000 people in the United States
annually with an increased incidence in aged
populations [1-3]. The most severe form of ALI is
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Acute Respiratory Distress Syndrome (ARDS). Both
the incidence of ALI/ARDS and subsequent mortality
rates for patients with ALI/ARDS are increasing,
totaling 70,000 deaths annually in the US alone [4].
Oxygen therapy is the most widely used intervention to
counteract hypoxemia in ALI/ARDS treatment [5].
However, in vivo and in vitro studies have indicated that
extended exposure to highly concentrated oxygen can
induce severe and lethal oxidative damage to the lung
[6]. The cellular and molecular mechanism regarding
how highly concentrated oxygen causes lung damage is
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well established. Both epithelial and endothelial cells of
the lung are among the major target cells that are
severely damaged by oxygen toxicity [7, 8].
Endogenously generated reactive oxygen species (ROS)
under hyperoxic conditions cause dysfunction and
apoptosis of these cell types, which in turn accelerate
inflammatory responses such as immune cell recruitment
and secretion of inflammatory cytokines [9, 10]. While
the clinical relevance of lung epithelial cell damage to
ALI/ARDS has been extensively studied, the
involvement of endothelial cells in these conditions
remains unclear. Especially, it is unclear how lung
vascular endothelial cells restore their functional integrity
under recovery phase after hyperoxic conditions.
Currently, there are various animal models available to
study ALI/ARDS; among which, hyperoxia-induced
lung injury model has been most widely used as a
feasible tool to directly induce elevation of oxidants in
the lung [11]. Long-term exposure to hyperoxia causes
buildup of ROS and decreases cell viability [6].
Furthermore, hyperoxia-induced lung injury model
involves a negligible amount of lung fibrosis when
compared to other lung injury models [4, 12]. Thus, it is
well established that there are many features shared
between hyperoxia-induced lung injury model and
ALI/ARDS [13]. Hyperoxic insult to the lung generates
oxidative stress, which leads to the accumulation of 4hydroxynonenal (4-HNE), a toxic aldehyde. 4-HNE is an
alpha beta unsaturated aldehyde formed by lipid
peroxidation. 4-HNE causes mitochondrial damage and
cell transduction impairment, as previously reported [1315]. 4-HNE also causes harmful effects on a variety of
tissues and cell types [14, 16-19]. ALDH2 has been
demonstrated to be a promising target because it
metabolizes and counteracts 4-HNE [20]. Therefore, it is
reasonable to investigate whether activation of ALDH2
attenuates hyperoxia-induced mitochondrial damage and
cell death in lung epithelial and endothelial cells.
Alda-1, a most widely used ALDH2 agonist, reduces
the Km value (Michaelis constant) and increases the Vmax (maximum velocity) of the acetaldehyde
metabolizing reaction catalyzed by ALDH2 [20].
Studies have demonstrated that Alda-1 binds to ALDH2
near the Glu286 and Cys302 residues and thereby
enhances the catalytic activity [20-22]. Preclinical
effects of Alda-1 have been evaluated in a variety of
cell lines and organs. Administration of Alda-1 is
known to i) enhance the ALDH2 function in epithelial
cells and human umbilical endothelial cells and ii)
reduce cerebral and cardiac ischemia, by reducing toxic
4-HNE levels [16, 19, 23, 24].
Lung vascular endothelial cells play an important role in
maintaining the functional integrity of vasculature and
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hence lung homeostasis. They are also involved in
vascular remodeling, angiogenesis, coagulation, and
blood circulation [25]. Given their integral roles in lung
homeostasis, death of lung vascular endothelial cells
and consequent loss of vascular integrity represents a
significant contribution to the pathogenesis of oxidative
stress-induced lung injury [6]. Experimentally delivered
high level oxygen triggers epithelial and endothelial cell
damage in vivo, leading to disruption of blood-air
barrier and ending up in edema of the lung. This is a
well-known initial disease progression step of
ALI/ARDS [26]. While ALDH2 has been demonstrated
to serve as a shield against oxidative stress-mediated
cell damage in lung epithelial cells [23], it is not known
whether ALDH2 protects against oxidative stress in
lung vascular endothelial cells.
In the current study we attempt to determine if the
pretreatment with Alda-1 is sufficient to attenuate
hyperoxia-induced oxidative damage in lung vascular
endothelial cells.

RESULTS
ALDH2 activation through Alda-1 treatment
attenuates 4-HNE accumulation in pulmonary
vascular endothelial cells
Oxidative stress causes accumulation of 4-HNE, a
highly electrophilic aldehyde that is harmful to the cell.
ALDH2 catalyzes the conversion of 4-HNE to an
inactive form 4-hydroxy-2-nonenoic acid (4-HNA) [27].
Alda-1, an ALDH2 activator has been shown to protect

Figure 1. Activation of ALDH2 diminishes hyperoxiainduced 4-HNE accumulation in lung vascular
endothelial cells. HMVEC were cultured in three different

conditions: NO (normoxia), HO (48 hrs of hyperoxia) or
HO+Alda-1 (Alda-1 pretreatment followed by 48 hrs of
hyperoxia). Whole cell lysates (50 µg protein equivalent) were
subjected to ELISA to evaluate the amount of 4-HNE content.
The results are shown in mean ± SEM (n=3). Data presented are
representative of three independent experiments.
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numerous cell types against oxidative stress by
increasing ALDH2 activity [16, 28-31]. However, no
study has verified its protective effect on lung vascular
endothelial cells. To verify its anti-oxidative effect on
lung endothelial cells, we exposed human
microvascular endothelial cells (HMVEC) to hyperoxia
in the presence or absence of Alda-1. Hyperoxia causes
55% increase in 4-HNE compared to Normoxia and
pretreatment with Alda-1 in hyperoxic conditions
causes 26% decrease compared to hyperoxia. The
results show that pretreatment with Alda-1 attenuates
hyperoxia-induced 4-HNE accumulation in HMVEC
(Fig. 1). These results indicate that ALDH2 plays a vital
role in protecting lung vascular endothelial cells
through the catalytic inactivation of 4-HNE.
ALDH2 activation through Alda-1 treatment
attenuates
hyperoxia-induced
apoptosis
in
pulmonary vascular endothelial cells
Oxidative stress causes apoptotic and non-apoptotic cell
death in many cell types. Cytochrome C and Bax levels
reflect apoptotic cell death [14]. To assess whether
ALDH2 activation through Alda-1 suppresses apoptosis

Figure 3. ALDH2 activation via Alda-1 attenuates
hyperoxia-induced increase in Bax expression in lung
vascular endothelial cells. (a) Whole cell lysates extracted

from HMVEC cultured under different conditions (normoxia, 48
hrs of hyperoxia, or Alda-1 pretreatment followed by 48 hrs of
hyperoxia) were evaluated for Bax levels by Western blotting.
Equal amounts of protein (20µg) were loaded per each lane. (b)
Expression of Bax was normalized to β-actin and presented in
arbitrary units. The results are shown in mean ± SEM (n=3).
Data presented are representative of two independent
experiments.

signaling caused by oxidative stress in HMVEC, the
protein levels of Cytochrome C and Bax in whole cell
lysate were quantified by Western blotting. The results
show that hyperoxia causes 2.5- and 1.5-fold increase in
Cytochrome C and Bax levels, respectively, compared
to normoxic controls (Fig. 2 and 3). HMVEC treated
with Alda-1 prior to hyperoxia resulted in a significant
64% and 25% decrease in the expression of Cytochrome
C and Bax, respectively, compared to those untreated
with Alda-1 (Fig. 2 and 3). These results indicate that
ALDH2 activation protects from oxidative stressinduced apoptosis in lung vascular endothelial cells.

Figure 2. Activation of ALDH2 attenuates hyperoxiainduced increase in cytochrome c expression in lung
vascular endothelial cells. (a) Whole cell lysates extracted

ALDH2 activation through Alda-1 treatment
increases ALDH2 expression in pulmonary
endothelial cells during hyperoxia

from HMVEC cultured under different conditions (normoxia, 48
hrs of hyperoxia, or Alda-1 pretreatment followed by 48 hrs of
hyperoxia) were evaluated for cytochrome C levels by Western
blotting. Equal amounts of protein (20µg) were loaded per each
lane. (b) Expression of Cytochrome C was normalized to β-actin
and presented in arbitrary units. The results are shown in mean
± SEM (n=3). Data presented are representative of two
independent experiments.
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Recent studies have shown that Alda-1 does not affect
the expression levels of ALDH2 but does increase
ALDH2 enzymatic activity in various cell types [19,
32]. However, no study has examined the effects of
Alda-1 on the expression and enzymatic activity of
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ALDH2 activation through Alda-1 treatment
protects pulmonary vascular endothelial cells
against hyperoxia-induced mitochondrial damage
Decrease in the mitochondrial membrane potential
(membrane
depolarization;
ΔΨm)
represents
mitochondrial damage [33]. A fluorescent dye, JC-1,
allows us to detect mitochondrial membrane
depolarization as a shift in fluorescent signal from red
(JC-1 aggregates) to green (JC-1 monomer) and thereby
evaluate the extent of the mitochondrial damage of the
cells in vitro.
To evaluate the favorable effect of ALDH2 on
mitochondrial function on lung vascular endothelial
cells, JC-1 assay was performed on HMVEC cultured
under different conditions. As an index for the
functional integrity of mitochondria, the ratio of red to
green signals was used (referred to as mitochondrial
functionality index hereinafter). The results show that
HMVEC exposed to hyperoxia vs normoxia controls
display 48% significant decrease in mitochondrial
functionality index. Cells pretreated with Alda-1 prior
to hyperoxia exposure show 62% significant increase in
mitochondrial functionality index when compared to the
cells untreated with Alda-1 prior to hyperoxia. These
results suggest that ALDH2 plays a pivotal role in
maintaining the functional integrity of mitochondria in
lung vascular endothelial cells (Fig. 6). The results also
indicate that ALDH2 activation helps to attenuate
oxidative stress-induced mitochondrial damage in lung
vascular endothelial cells.

Figure 4. ALDH2 activation through Alda-1
pretreatment enhances ALDH2 expression in lung
vascular endothelial cells under hyperoxia. (a) Whole

cell lysates extracted from HMVEC cultured under different
conditions (normoxia, 48 hrs of hyperoxia, or Alda-1
pretreatment followed by 48 hrs of hyperoxia) were
evaluated for ALDH2 levels by Western blotting. Equal
amounts of protein (20µg) were loaded per each lane. (b)
Expression of ALDH2 was normalized to β-actin and
presented in arbitrary units. The results are shown in mean ±
SEM (n=3). Data presented are representative of three
independent experiments.

ALDH2 in lung vascular endothelial cells. In order to
answer this question, the expression and enzymatic
activity of ALDH2 were evaluated. The results show
that hyperoxia alone without Alda-1 treatment causes
26% increase in ALDH2 expression in HMVEC though
the difference is not significant (p=0.064) (Fig. 4). Cells
pretreated with Alda-1 prior to hyperoxia show further
increase in ALDH2 expression compared to those
untreated with Alda-1 prior to hyperoxia though the
difference is not significant (p = 0.069) (Fig. 4). Next,
we evaluated the ALDH2 activity. The results show that
hyperoxia-treated cells show slight decrease in ALDH2
activity compared to normoxic controls (Fig. 5). Cells
pretreated with Alda-1 prior to hyperoxia display 23%
increase in ALDH2 activity compared to those
untreated with Alda-1 prior to hyperoxia (p=0.48) (Fig.
5). These results indicate that Alda-1 treatment
counteract against oxidative stress-induced decrease in
the expression and activity of ALDH2 in lung vascular
endothelial cells.
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Figure 5. ALDH2 activation through Alda-1
pretreatment attenuates hyperoxia-induced decrease
in ALDH2 activity in lung vascular endothelial cells.

Mitochondrial lysates extracted from HMVEC cultured under
different conditions (normoxia, 48 hrs of hyperoxia, or Alda-1
pretreatment followed by 48 hrs of hyperoxia) were
subjected to an enzymatic assay to evaluate ALDH2 activity.
The results are shown in mean ± SEM (n=3). Data presented
are representative of three independent experiments
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Figure 6. ALDH2 activation protects lung vascular endothelial cells against hyperoxia-induced mitochondrial membrane
damage. (a) HMVEC cultured under different conditions (normoxia, 48 hrs of hyperoxia, or Alda-1 pretreatment followed by 48 hrs of

hyperoxia) were subjected to JC-1 staining (magnification=200x). (b) Fluorescence intensities of green and red signals were quantified
for each image using ImageJ software. The calculated ratios of red to green signals were expressed in arbitrary units. The results are
shown in mean ± SEM (n=3). Data presented are representative of three independent experiments.

DISCUSSION
For the first time, it is demonstrated in the current study
that ALDH2 activation through Alda-1 treatment has
the potential to mitigate hyperoxia-induced functional
deterioration of ALDH2 in pulmonary vascular
endothelial cells. ALDH2 activation through Alda-1
administration also resulted in significant decrease in
Cytochrome C expression and dramatically improved
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mitochondrial membrane potential. Alda-1 displayed
distinguished protection against hyperoxia in HMVEC,
as shown by the diminished levels of Bax, an apoptotic
activator indicative of mitochondrial stress.
Aging is known to cause significant changes in
pulmonary physiology, including alterations of the
structure of lungs and the mechanical properties of gas
exchange [34]. Almost all the patients suffering from
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ALI/ARDS receive oxygen therapy to counteract the
severe hypoxemia caused by pulmonary edema [35].
However ample evidence demonstrates that extended
exposure to highly concentrated oxygen can cause
oxidative stress-induced lung damage. Given that the
ability of the lung to maintain its homeostasis wanes
gradually with age, older patients are considered to be
more susceptible to toxic side effects of oxygen [36].
During hyperoxic exposure, the increased oxidative
stress results in intracellular accumulation of ROS,
thereby causing cellular damage and apoptosis that
culminates in tissue and organ failure [6, 37].
Mitochondrial ALDH2 plays a pivotal role in
preventing the accumulation of 4-HNE, oxidative stress,
apoptosis, and mitochondrial membrane damage [13,
19, 22, 38]. ALDH2 has also been implicated in
numerous age-related pathologies, such as ischemic
heart disease, Alzheimer’s disease, and Parkinson’s
disease. Accordingly, an ALDH2 activator Alda-1 has
been shown to reduce injuries in the heart, liver, brain,
kidney, and intestines. However, Alda-1 has not been
thoroughly tested in the lung [16, 28-31]. For the first
time, we have demonstrated the ALDH2 activation
through Alda-1 attenuates hyperoxia-induced cell
damage in lung vascular endothelial cells. We also
revealed that this protection by Alda-1 is mainly
through suppression of apoptosis and improvement of
mitochondrial membrane potential.
Previous studies show that hyperoxic exposure induces
the formation of 4-HNE-protein adducts, leading to the
functional loss of the adducted proteins [38, 39].
Moreover, such protein alterations result in impaired
cellular feedback, further promoting the production of
ROS and oxidative stress and ultimately leading to
cellular dysfunction and death [13, 32]. Our current
study for the first time shows that such ALDH2-assisted
cell protection occurs in lung vascular endothelial cells
as well.
Exposure of lung cells to hyperoxia for prolonged
durations causes a greater decrease in mitochondrial
membrane potential mediated through oxidative stress.
[7, 8]. Hyperoxia-induced loss of mitochondrial
membrane potential was significantly attenuated by
pretreatment with Alda-1 (Figure 6a). The restoration of
the expression and activity of ALDH2 and improvement
of mitochondrial membrane potential in Alda-1
pretreated lung vascular endothelial cells indicate that
ALDH2 is a promising therapeutic target for protecting
endothelial cells from oxidative stress-induced cellular
damage (Figures 6, 5 & 4, respectively).
Epithelial and endothelial cells are the key components
of the blood–air barrier in the lung and its disruption
causes increased lung permeability, leading to an influx
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of fluid from vasculature into the alveoli [26].
Endothelial cells apoptosis is a key initial event that
characterizes ALI/ARDS [40]. Therefore, prevention of
endothelial cell apoptosis is a reasonable therapeutic
intervention for the treatment of ALI/ARDS. In the
current study, we show for the first time that ALDH2
activation through Alda-1 mitigates hyperoxia-induced
increase in apoptosis-related proteins, Bax and
Cytochrome C, in lung vascular endothelial cells. Since
hyperoxia-induced accumulation of 4-HNE as well as
the mitochondrial membrane potential abnormality are
also restored by Alda-1 pretreatment, we surmise that
the ALDH2 protects endothelial cells from oxidative
stress-induced apoptosis by inactivating 4-HNE and
thereby precluding mitochondrial membrane damage.
Future in vivo studies are required to show that 4-HNE
pretreatment attenuates hyperoxia-induced endothelial
cells death and increased lung permeability.
In summary, these findings suggest that lung vascular
endothelial cells can be protected against hyperoxic
damage through ALDH2 activation by use of Alda-1.
Administration of Alda-1 has the potential to be applied
as a novel therapeutic tool to preclude and/or diminish
oxygen therapy-associated lung injury in patients with
ALI/ARDS. Further in vivo studies are needed to
determine the efficacy and tolerability of Alda-1
treatment to assess its clinical usefulness.

MATERIALS AND METHODS
Cell culture
HMVEC were purchased from Lonza and maintained in
EGM-2 MV bullet kit prepared according to
manufacturer instructions (Lonza, Walkersville, MD).
Cells were cultured at 37 ºC in a 5% carbon dioxide
humidified incubator to maintain sufficient cell growth.
The cultured cells were validated for confluence
(around 70 %) and exposed to hyperoxia for 48 hours
with and without Alda-1 pretreatment.
Alda-1
Alda-1 (N-(1,3-Benzodioxol-5-ylmethyl)-2,6-dichlorobenzamide) (St. Louis, MO) was purchased from Sigma
Aldrich, protected from light, and 20µM concentrations
were used for experiments.
Oxidative stress assay
Oxidative stress was measured by OxiSelect™ 4-HNE
adduct competitive ELISA kit (Cell Biolabs, San Diego,
CA) according to the instructions. Whole cell lysate (50
µg protein equivalent) for each sample was used for the
assay.
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Western blot
HMVEC were cultured, confluence was confirmed (70
%), and the cells were exposed to hyperoxia with or
without Alda-1 for 48 hours. The oxygen level was
monitored by the proOX p100 sensor (Biospherix, NY).
After hyperoxia, the cells were harvested and the
collected cell pellets were suspended in lysis buffer
(20mM Tris HCL, pH7.4, 150mM Nacl, 0.5% Triton-x
100). After centrifugation at high speed (14000g) for 15
minutes at 4° C, the supernatant was collected. The
protein concentration of each sample was determined by
BCA assay kit (Pierce, Rockford, IL). Equivalent
amounts of protein (20µg) were run using SDS-PAGE
on a 4-20% tris-glycine gel (BioRad, Hercules, CA).
The protein samples on the gel were then transferred to
PVDF membranes. After blocking in 5% skim milk, the
membranes were incubated with primary and then
secondary antibodies. The antibodies used are antiCytochrome C, anti β-actin (Cell signaling technologies,
Beverly, MA), anti-Bax (Santa Cruz, Dallas, TX), antiALDH2 (Novus Bio, Centennial, CO). The secondary
antibodies used were HRP-conjugated anti-rabbit and
mouse IgG antibodies (Jackson Immunoresearch
laboratory, Inc., Westgrove, PA). The bands were
developed using pierce ECL (Thermo Fischer scientific,
Hudson, NH) and the detected bands were scanned and
analyzed densitometrically by NIH ImageJ software.
JC-1 staining
HMVEC were plated at a density of 10 cells in CELL
view dish with glass bottom (Thomas scientific,
Swedesboro, NJ). When cells reached 70% confluence,
they were exposed to hyperoxia for 48 hours with or
without Alda-1. Following hyperoxia, the HMVEC-L
were washed by HBSS solution (with CaCl2 and MgCl2)
(Gibco, Waltham, MA). After washes, the HMVEC-L
were treated with JC-1 (2.5 µM) (Thermo Fisher,
Waltham, MA) at 37° C for 15 minutes and washed in
HBSS three times and placed into the media. Live cell
imaging was conducted using fluorescence microscopy
(Olympus, Tokyo) and magnification was 200X.
Around 100 cells were quantified from each group. The
green and red images were captured in fluorescence and
the mean signal intensity of each image was quantified
using ImageJ software.
4

ALDH2 activity
The enzymatic activity of ALDH2 was measured by
transformation of acetaldehyde to acetic acid [16]. At
the end of each treatment, HMVEC-L were harvested
and the cell pellets were re-suspended in 300 µL of
ALDH2 assay buffer (10 mM DTT, 100 mM Tris-HCl
pH 8.0, 20% glycerol, 1% Triton X-100). Cell
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suspension was then centrifuged at 55000g for 30
minutes at 4° C. The supernatant was collected and
utilized to detect the activity of ALDH2. The assay
mixture (1 mL) contains 10mM NAD+, 100mM sodium
pyrophosphate, 10 mM acetaldehyde, and 100 µg
protein equivalent. Acetaldehyde was added to the
cuvette immediately before the reaction was started.
The NADH generated de novo was determined by
spectrophotometric absorbance at 340 nm. The activity
of the ALDH2 enzyme was expressed as nmol NADH/
minute/ mg protein.
Statistical Analysis
All experiments were conducted with n=3 per group and
values were indicated as means ± SE. Statistical
significance was calculated by using Microsoft excel
and T-tests were two tailed; values less than p<0.05
were considered significant (*p<0.05, **<0.005).
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